Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
Animals
Antigens, Neoplasm
/ immunology
Cell Line
Cell Line, Tumor
HEK293 Cells
Humans
Immune Checkpoint Inhibitors
/ immunology
Immunotherapy, Adoptive
/ methods
Lung Neoplasms
/ immunology
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Receptor Tyrosine Kinase-like Orphan Receptors
/ immunology
Receptors, Antigen, T-Cell
/ immunology
Receptors, Chimeric Antigen
/ immunology
T-Lymphocytes
/ immunology
Tumor Microenvironment
/ immunology
CAR-T cells
CXCR3
CXCR6
KP
ROR1
alveolar macrophage
immunogenic cell death
lung adenocarcinoma
oxaliplatin
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
08 02 2021
08 02 2021
Historique:
received:
13
05
2020
revised:
18
09
2020
accepted:
13
11
2020
pubmed:
29
12
2020
medline:
29
9
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Adoptive therapy using chimeric antigen receptor-modified T cells (CAR-T cells) is effective in hematologic but not epithelial malignancies, which cause the greatest mortality. In breast and lung cancer patients, CAR-T cells targeting the tumor-associated antigen receptor tyrosine kinase-like orphan receptor 1 (ROR1) infiltrate tumors poorly and become dysfunctional. To test strategies for enhancing efficacy, we adapted the Kras
Identifiants
pubmed: 33357452
pii: S1535-6108(20)30597-3
doi: 10.1016/j.ccell.2020.11.005
pmc: PMC7878409
mid: NIHMS1649983
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Immune Checkpoint Inhibitors
0
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Receptor Tyrosine Kinase-like Orphan Receptors
EC 2.7.10.1
Banques de données
ClinicalTrials.gov
['NCT02706392']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
193-208.e10Subventions
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA228944
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA114536
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests S.S. and S.R.R. are inventors on a patent (“Immunogenic chemotherapy markedly enhances the efficacy of ROR1 CAR T cells in lung adenocarcinoma”; PCT/US2018/049812) filed by Fred Hutchinson Cancer Research Center and licensed by Lyell Immunopharma. S.S. holds equity and has served as a consultant for Lyell Immunopharma. D.G.M. has received research funding from Kite Pharma, Juno Therapeutics, and Celgene, and has served on advisory boards for Kite Pharma, Gilead, Genentech, Novartis, and Eureka Therapeutics. S.R.R. was a founder, has served as an advisor, and has patents licensed to Juno Therapeutics; is a founder of and holds equity in Lyell Immunopharma; and has served on the advisory boards for Adaptive Biotechnologies and Nohla. C.R. is named inventor on US Patent 9,758,586 claiming anti-ROR1 monoclonal antibodies R11 and R12 and is on the advisory board of NBE-Therapeutics. No potential conflicts of interest were disclosed by the other authors.
Références
Blood. 2011 Aug 4;118(5):1255-63
pubmed: 21653320
Behav Brain Res. 1990 Jan 22;36(3):229-49
pubmed: 2310488
Annu Rev Immunol. 2019 Apr 26;37:145-171
pubmed: 30526160
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Clin Cancer Res. 2018 Jan 1;24(1):95-105
pubmed: 29061641
Nature. 2019 Feb;566(7745):496-502
pubmed: 30787437
Clin Cancer Res. 2017 Jun 15;23(12):3061-3071
pubmed: 27852699
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
Nucleic Acids Res. 2013 Apr;41(8):4378-91
pubmed: 23444143
Nature. 2014 Dec 18;516(7531):428-31
pubmed: 25337879
Nat Immunol. 2009 Apr;10(4):403-11
pubmed: 19252491
Blood. 2010 Nov 25;116(22):4532-41
pubmed: 20702778
PLoS Comput Biol. 2013;9(8):e1003118
pubmed: 23950696
Cancer Cell. 2019 Mar 18;35(3):489-503.e8
pubmed: 30889382
Annu Rev Immunol. 1997;15:323-50
pubmed: 9143691
Front Oncol. 2013 Aug 15;3:211
pubmed: 23967403
Nature. 2019 Mar;567(7749):530-534
pubmed: 30814732
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Curr Opin Immunol. 2013 Apr;25(2):192-9
pubmed: 23465466
Nat Rev Drug Discov. 2011 Jun;10(6):417-27
pubmed: 21629292
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
Hum Gene Ther Clin Dev. 2013 Sep;24(3):134-42
pubmed: 24099518
Genome Biol. 2014;15(12):550
pubmed: 25516281
BMC Cancer. 2013 Nov 11;13:540
pubmed: 24215488
J Immunol. 2018 Jan 15;200(2):459-468
pubmed: 29311388
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Cancer Immunol Res. 2015 Feb;3(2):206-16
pubmed: 25355068
Cancer Res. 2006 Jan 1;66(1):508-16
pubmed: 16397267
Oncoimmunology. 2015 Mar 06;4(2):e988098
pubmed: 25949885
PLoS One. 2011;6(6):e21018
pubmed: 21698301
Sci Transl Med. 2014 Nov 5;6(261):261ra151
pubmed: 25378643
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Nat Protoc. 2009;4(7):1064-72
pubmed: 19561589
Clin Cancer Res. 2011 Jul 15;17(14):4719-30
pubmed: 21610146
Clin Cancer Res. 2010 Nov 15;16(22):5458-68
pubmed: 20889916
Mol Ther. 2002 Apr;5(4):479-84
pubmed: 11945076
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
Cancer Cell. 2019 Jun 10;35(6):885-900.e10
pubmed: 31185212
Cancer Immunol Res. 2015 Feb;3(2):125-35
pubmed: 25212991
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Immunity. 2014 Nov 20;41(5):830-42
pubmed: 25517615
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Protoc. 2014 Jan;9(1):209-22
pubmed: 24385150
Cell Syst. 2019 Apr 24;8(4):281-291.e9
pubmed: 30954476
J Immunother. 2010 Oct;33(8):780-8
pubmed: 20842059
Nature. 2018 Mar 22;555(7697):538-542
pubmed: 29539636
Cancers (Basel). 2019 May 14;11(5):
pubmed: 31091832
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
Nature. 2019 Dec;576(7786):293-300
pubmed: 31802004
Ann Oncol. 2017 Dec 1;28(suppl_12):xii18-xii32
pubmed: 29045511
PLoS One. 2018 Jun 12;13(6):e0198359
pubmed: 29894476
Nat Commun. 2019 Sep 5;10(1):4016
pubmed: 31488817
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
J Neurosci. 2012 Feb 29;32(9):3154-63
pubmed: 22378888
Clin Cancer Res. 2015 Sep 15;21(18):4062-72
pubmed: 26059190
Oncogene. 2016 Feb 18;35(7):816-26
pubmed: 25961926
Eur J Immunol. 2020 May;50(5):712-724
pubmed: 31981231
Blood. 2009 Jun 18;113(25):6392-402
pubmed: 19377047
Nat Rev Clin Oncol. 2013 May;10(5):267-76
pubmed: 23546520
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Clin Cancer Res. 2013 Jun 15;19(12):3153-64
pubmed: 23620405
Cancer Cell. 2011 Jan 18;19(1):72-85
pubmed: 21251614